Dandelion root (Taraxacum officinale)
-Various phytochemicals, including flavonoids and phenolic compounds, which have antioxidant properties.
-Root extract can induce apoptosis
-Anti-inflammatory properties
-Immune System Support
Dosage: dried root 2-8g/d. Extract 250-500mg/d Tea 1-2g, 1-3x/d
aqueous Dandelion flower extracts (DFE), dandelion leaf extract (DLE), and dandelion root extract (DRE) may have different effects.
Common Names: Blowball, Puffball, Lion's tooth, Pu gong ying, Swine snout, Wild endive
Taraxacum officinale is rich in flavonoids (e.g., luteolin, quercetin glycosides), phenolic acids (chicoric, chlorogenic, and caffeic acids), terpenoids (taraxasterol, taraxerol), sesquiterpene lactones (taraxinic acid β-D-glucopyranosyl ester), and phytosterols (β-sitosterol, cycloartenol)
Dandelion Root — Dandelion root is the root material or root extract of Taraxacum officinale, a polychemical botanical preparation containing phenolic acids, flavonoids, sesquiterpene lactones, triterpenes, inulin-type carbohydrates, and other phytochemicals. It is formally classified as a botanical dietary supplement or herbal extract rather than a defined single-molecule oncology drug. Standard abbreviations include DRE for dandelion root extract and T. officinale for the plant species. Current oncology relevance is mainly preclinical, with repeated in-vitro and xenograft signals but no completed convincing human cancer efficacy trial.
Primary mechanisms (ranked):
- Selective programmed cell death induction in cancer cells, especially extrinsic caspase-8 signaling with downstream mitochondrial destabilization and caspase execution.
- Mitochondrial stress and pro-death autophagy, including loss of mitochondrial integrity and context-dependent mitochondrial ROS involvement.
- Multi-pathway growth suppression through cell-cycle disruption, PI3K-Akt/JAK-STAT/PPAR pathway modulation, and reduced survival signaling.
- Anti-invasive and anti-metastatic signaling, including reduced migration/invasion phenotypes and reduced MMP-9/IL-1β expression in some models.
- Chemosensitization or adjunctive enhancement in preclinical models, especially with taxol and mitoxantrone in prostate cancer models.
- Anti-inflammatory and antioxidant effects in non-cancer contexts; these are biologically relevant but not the central cancer-killing mechanism.
Bioavailability / PK relevance: Dandelion root extract is not a standardized single active agent, so formal human PK is not well established. Oral use is plausible as a botanical preparation, but systemic exposure to the same complex extract composition used in cell culture is unknown. Inulin-rich root material may also act partly through gastrointestinal or microbiome-facing exposure rather than direct plasma-equivalent exposure.
In-vitro vs systemic exposure relevance: Many anticancer experiments use crude extract concentrations in the mg/mL range and exposure windows of 24–96 hours. These concentrations should not be assumed to be systemically achievable after oral use. Colorectal and gastrointestinal tumor models may have relatively better luminal-exposure plausibility than distant solid-tumor systemic exposure, but clinical translation remains unproven.
Clinical evidence status: Preclinical. Evidence includes cell-line studies, some xenograft studies, and case-report-level human observations. A phase I cancer trial effort was reported as Health Canada-approved/recruiting, but there is no clear completed trial demonstrating cancer efficacy. It should not be treated as an established anticancer therapy.
Safety / deployment status: Dandelion is widely marketed as a food/herbal dietary supplement and is generally considered likely safe at food-level intake, but concentrated medicinal doses have less safety evidence. Important constraints include possible allergy in Asteraceae-sensitive individuals, theoretical interactions with antidiabetic, anticoagulant/antiplatelet, lithium, diuretic, and other medications, and uncertainty in pregnancy or breastfeeding. Hormone-sensitive cancer caution is reasonable because some preclinical evidence suggests estrogenic activity and possible stimulation of hormone-sensitive breast cancer models.
Dandelion Root Cancer Mechanism Table
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Extrinsic apoptosis and caspase activation |
↑ caspase-8, ↑ Annexin V positivity, ↑ programmed cell death |
↔ or lower toxicity in tested PBMCs, fibroblasts, colon mucosa, and mammary epithelial cells |
G |
Selective cancer-cell apoptosis |
Most central recurring anticancer signal across melanoma, leukemia, colorectal, pancreatic, prostate, and breast models; strongest evidence remains in vitro. |
| 2 |
Mitochondrial destabilization |
↓ mitochondrial integrity, ↓ mitochondrial membrane potential, ↑ downstream death signaling |
↔ or relatively spared in several comparator normal-cell models |
G |
Amplifies intrinsic death execution |
Mitochondrial injury appears downstream of extrinsic death signaling in some leukemia models and more direct in melanoma/pancreatic models. |
| 3 |
Pro-death autophagy |
↑ autophagy with apoptosis linkage |
↔ uncertain |
G |
Contributes to programmed cell death |
Reported in CMML and pancreatic cancer studies; autophagy direction should be interpreted as pro-death in those models, not automatically cytoprotective. |
| 4 |
Cell cycle arrest |
↑ S phase and G2/M accumulation, ↓ proliferation |
↔ or less affected in tested normal mammary epithelial cells |
G |
Restricts proliferation |
Best supported in newer breast cancer fractionation/proteomics work; extract-specific and concentration-dependent. |
| 5 |
PI3K-Akt and JAK-STAT survival signaling |
↓ PI3K/Akt-related survival proteins, ↓ JAK/STAT-associated signaling markers (model-dependent) |
↔ uncertain |
G |
Reduces survival signaling |
Mechanistic support is strongest in MDA-MB-231 fraction studies; requires caution because crude extracts and fractions differ substantially. |
| 6 |
Mitochondrial ROS increase secondary |
↑ ROS (context-dependent), ↑ oxidative mitochondrial stress |
↔ uncertain; antioxidant effects may occur in normal inflammatory injury models |
R/G |
Stress-mediated death amplification |
ROS is not uniformly the primary DRE mechanism; in prostate work, DRE apoptosis was described as caspase-dependent while lemongrass was more ROS-dependent. |
| 7 |
Migration invasion and metastasis markers |
↓ migration, ↓ invasion, ↓ MMP-9, ↓ IL-1β, ↑ KAI1 (model-dependent) |
↔ uncertain |
G |
Anti-invasive phenotype |
Observed in breast and pediatric/neuroblastoma models; translational strength is lower than the apoptosis signal. |
| 8 |
Chemosensitization |
↑ taxol-induced apoptosis, ↑ mitoxantrone-induced apoptosis, ↓ xenograft tumor burden with oral extract in prostate models |
↔ or reduced toxicity signal in selected comparator normal-cell assays |
G |
Adjunctive enhancement |
Preclinical adjunct signal only; drug interaction risk means this should not be assumed safe with chemotherapy without oncology supervision. |
| 9 |
Inflammation and NF-κB linked signaling |
↓ inflammatory signaling markers (context-dependent) |
↓ inflammatory injury markers in non-cancer models |
G |
Anti-inflammatory modulation |
Relevant to tumor microenvironment hypotheses but less directly established as a dominant cancer-cell killing mechanism for root extract. |
| 10 |
NRF2 antioxidant axis |
↔ insufficient direct cancer-specific evidence for root extract |
↑ antioxidant defense may occur in injury/metabolic models (context-dependent) |
G |
Not a core cancer axis |
Do not tag NRF2 as a primary DRE anticancer mechanism unless a specific study directly supports it in the target cancer model. |
| 11 |
Clinical Translation Constraint |
High in-vitro extract concentrations; variable extract chemistry; no validated human anticancer exposure target |
Food-level safety generally favorable but concentrated-dose interaction and allergy concerns remain |
G |
Limits clinical inference |
Evidence is promising but mostly preclinical; oral dosing cannot be translated directly from mg/mL cell-culture exposure. |
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
|